Dr. Bissonnette will be speaking on a study sponsored by RAPT
We are thrilled to announce that Dr. Bissonnette will be speaking on a study sponsored by RAPT at the ‘Late-breaking abstract for oral presentation’ session during this year’s 30th Anniversary EADV Congress!
The session will cover the clinical safety and efficacy of RPT193, an oral CCR4 inhibitor, citing results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate to severe atopic dermatitis.
This virtual session will take place on Sept 30th, 2021, from 3:15-3:30 CEST (Central European Summer Time).
We’re gearing up for a great session with the EADV and look forward to seeing you all there!